CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.2699
+0.0417 (18.25%)
Oct 19, 2026, 12:14 PM EST
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
396.62M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2026 | - | - | - |
| May 31, 2025 | - | - | - |
| May 31, 2024 | - | - | - |
| May 31, 2023 | - | - | - |
| May 31, 2022 | 266.00K | - | - |
| May 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 243.07M |
| Sangamo Therapeutics | 34.56M |
| Nuo Therapeutics | 5.20M |
| Northwest Biotherapeutics | 2.17M |
| Silence Therapeutics | 615.00K |
| Arch Biopartners | 113.25K |
CytoDyn News
- 4 days ago - CytoDyn to Host Investor Webcast - GlobeNewsWire
- 5 days ago - CytoDyn Quarterly report: Q1 2027 - Filings
- 11 days ago - CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026 - GlobeNewsWire
- 21 days ago - CytoDyn Proxy statement: Proxy filing - Filings
- 24 days ago - CytoDyn Registration statement: Registration filing - Filings
- 4 weeks ago - CytoDyn Transcript: Life Sciences Virtual Investor Forum Conference - Transcripts
- 4 weeks ago - CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th - GlobeNewsWire
- 6 weeks ago - CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab - GlobeNewsWire